PharmaSGP Achieves Over €100 Million in Revenues for 2023, Eyes Expansion in 2024

PharmaSGP Holding SE, a prominent German over-the-counter pharmaceutical company, reported a significant achievement for the 2023 financial year, surpassing the €100 million revenue threshold for the first time. The company ended the year with revenues totaling €101.1 million, marking an increase of 17.8% from the previous year’s €85.8 million. This growth is attributed to strong organic development driven by its strategic platform initiatives.

The company also saw an increase in its adjusted EBITDA, reaching €34.1 million, up 20.8% compared to 2023. The adjusted EBITDA margin improved to 33.7%, enhancing the financial health of the business.

Looking forward, PharmaSGP anticipates continued growth in 2024, with revenue forecasts between €107.0 million and €112.0 million and an adjusted EBITDA ranging from €35.0 million to €38.0 million. These expectations reflect the company's confidence in the sustainability and efficacy of its growth strategy, even in a challenging market environment.

The full annual report for 2023 is expected to be released on April 29, 2024, which will provide more detailed insights into the company’s financial performance and strategic initiatives.